Introduction: in adults, adenomas are the most frequent causes of pituitary tumours. The objective was to characterize its epidemiological and clinical aspects, as well as its therapeutic modalities in Senegal. Methodology: this was a multicenter, retrospective, descriptive and analytical study carried out from the Senegalese register of pituitary adenomas (2008-2022). Results: 242 patients were collected with an average age of 42.4 ± 13 years and a sex ratio (M/F) of 0.91. The mean consultation time was 19.7 ± 23 months. The circumstances of discovery were pituitary apoplexy (11 cases, 4.54%), tumor syndrome (176 cases, 72.72%), gonadal manifestations (103 cases, 42.56%), dysmorphic syndrome (21 cases, 8.68%), hypercorticism (15 cases, 6.19%). Morphologically, it was a macroadenoma (197 cases, 81.40%), an extensive adenoma (22 cases, 9.10%). The hormonal profile was lactotropic hypersecretion (80 cases, 33.05%), somatotropic (13 cases, 5.39%), corticotropic (14 cases, 5.78%), mixed (9 cases, 3.71%). The factors significantly associated with prolactinoma were young age (p = 0.000), female sex (p = 0.000), long consultation delay (p = 0.000) and microadenoma (p = 0.001). Only arterial hypertension was associated with acromegaly (p = 0.000). We found a significant correlation between Cushing’s disease and microadenomas (p = 0.000). Non-secreting adenomas were significantly associated with advanced age (p = 0.000), long delay in consultation (p = 0.000), male gender (p = 0.000), tumor syndrome (p = 0.001) and macroadenomas (p = 0.000). Pituitary surgery was effective in 173 patients (71.49%) including 166 cases (68.59%) by transphenoidal approach. Postoperative incidents were transient diabetes insipidus in 82 cases (47.39%), cerebrospinal fluid leak (20 cases, 11.56%). Death was observed in 18 patients in the entire series (7.44%). The latter had a tumor syndrome (88.88%), a macroadenoma (83.33%) and had undergone pituitary surgery (72.22%). Conclusion: pituitary pathology has become a reality with clinical and secretory polymorphism. The diagnostic delay explains the predominance of macroadenomas which are sources of pre and post-operative complications.
References
[1]
Buchfelder, M. and Fahlbusch, R. (2002) The “Classic” Transsphenoidal Approach for Resection of Pituitary Tumors. Operative Techniques in Neurosurgery, 5, 210-217. https://doi.org/10.1053/otns.2002.32498
[2]
González-González, J.L., López-Arbolay, O., Morales-Sabina, O., Martí-Piñeiro, J.F. and Vidal-Verdial, R. (2005) Transnasal-Transsphenoidal Endoscopic Surgery of the Sellar Región. Neurocirugía, 16, 27-33. https://doi.org/10.1016/S1130-1473(05)70431-0
[3]
Eloundou, N.J., Eyenga, V.C., Ngowe, M., Atangana, R. and Sosso, M.A. (2009) Pituitary Adenomas. Study of a Surgical Series of 16 Cases in Yaoundé Cameroon. African Journal of Neurological Sciences, 28, 55-60.
[4]
Fontana, E. and Gaillard, R. (2009) Epidemiology of Pituitary Adenoma: Results of the First Swiss Study. Revue Médicale Suisse, 5, 2171-2174. (In French)
[5]
Irfan, H., Shafiq, W., Siddiqi, A.I., et al. (2022) Prolactinoma: Clinical Characteristics, Management and Outcome. Cureus, 14, e29822. https://doi.org/10.7759/cureus.29822
[6]
Kars, M., Dekkers, O.M., Pereira, A.M. and Romijn, J.A. (2010) Update in Prolactinomas. Netherlands Journal of Medicine, 68, 104-112.
[7]
Mosbah, H., Brue, T. and Chanson, P. (2019) Acromegaly: Improving Care. Annals of Endocrinology, 80, S10-S18. https://doi.org/10.1016/S0003-4266(19)30112-X
[8]
El Habnouny, J., Assarrar, I., Berrabeh, S., Rouf, S. and Latrech, H. (2020) Pituitary Adenomas: Epidemiological, Clinical, Biological, Radiological and Therapeutic Aspects at the CHU Mohammed VI in Oujda. Annals of Endocrinology, 81, 294. (In French) https://doi.org/10.1016/j.ando.2020.07.418
[9]
Guiot, G., Thibaut, B. and Bourreau, M. (1959) Extirpation of Hypophyseal Adenomas by Trans-Septal and Trans-Sphenoidal Approaches. Ann Otolaryngol., 76, 1017-1031. (In French)
[10]
Hardy, J. (1969) Transphenoidal Microsurgery of the Normal and Pathological Pituitary. Neurosurgery, 16, 185-217. https://doi.org/10.1093/neurosurgery/16.CN_suppl_1.185
[11]
Daly, A.F. and Beckers, A. (2020) The Epidemiology of Pituitary Adenomas. Endocrinology and Metabolism Clinics of North America, 49, 347-355. https://doi.org/10.1016/j.ecl.2020.04.002
[12]
Chen, C., Hu, Y., Lyu, L., Yin, S., Yu, Y., Jiang, S., et al. (2021) Incidence, Demographics, and Survival of Patients with Primary Pituitary Tumors: A Seer Database Study in 2004-2016. Scientific Reports, 11, Article No. 15155. https://doi.org/10.1038/s41598-021-94658-8
[13]
Hima-Maiga, A., Fomekong, E., Vaz, G., Kelani, A., Abdoulwahab, I., Gaye, M., et al. (2021) Giant Pituitary Adenomas and Visual Disorders at Saint-Luc Clinics (Brussels): Meaning and Evolution apropos of 22 Cases. Health Sciences and Disease, 22, 38-43.
[14]
Abodo, J., Haidara, A., Koffi Dago, P., Kouassi, F., Hué, L.A. and Lokrou, A. (2016) [Profile of Pituitary Adenomas in Sub-Saharan Africa Apropos of 38 Cases]. Annals of Endocrinology, 77, 368-369. (In French) https://doi.org/10.1016/j.ando.2016.07.381
[15]
Fernandez, A., Karavitaki, N. and Wass, J.A.H. (2010) Prevalence of Pituitary Adenomas: A Community-Based, Cross-Sectional Study in Banbury (Oxfordshire, UK). Clinical Endocrinology, 72, 377-382. https://doi.org/10.1111/j.1365-2265.2009.03667.x
[16]
Daly, A.F., Rixhon, M., Adam, C., et al. (2006) High Prevalence of Pituitary Adenomas: A Cross-Sectional Study in the Province of Liège, Belgium. The Journal of Clinical Endocrinology & Metabolism, 91, 4769-4775. https://doi.org/10.1210/jc.2006-1668
[17]
Salami, A., Malomo, A.O., Shokunbi, T. and Akang, E. (2013) Immunohistochemical Analysis of Pituitary Adenomas in a West African Hospital. African Journal of Neurological Sciences, 32, 72-80.
[18]
Schaller, B. (2002) Gender-Related Differences in Growth Hormone-Releasing Pituitary Adenomas. A Clinicopathological Study. Pituitary, 5, 247-253. https://doi.org/10.1023/A:1025329900839
[19]
Mayanda, O.R.L., Ignaleamoko, T.G.S.P., Ekouele, M.H.B., et al. (2021) Management of Prolactin Pituitary Adenomas at the Brazzaville University and Hospital Center. Health Sciences and Disease, 22, 68-73.
[20]
Neggers, S.J., van Aken, M.O., Janssen, J.A., Feelders, R.A., de Herder, W.W. and van der Lely, A.J. (2007) Long-Term Efficacy and Safety of Combined Treatment of Somatostatin Analogs and Pegvisomant in Acromegaly. The Journal of Clinical Endocrinology & Metabolism, 92, 459-8601. https://doi.org/10.1210/jc.2007-1234
[21]
Bertagna, X. and Guignat, L. (2012) Recent Progress in the Treatment of Cushing’s Disease. Annals of Endocrinology, 73, 107-110. (In French) https://doi.org/10.1016/j.ando.2012.03.036
[22]
Espinosa, E., Sosa, E., Mendoza, V., et al. (2016) Giant Prolactinomas: Are They Really Different from Ordinary Macroprolactinomas? Endocrine, 52, 652-659. https://doi.org/10.1007/s12020-015-0791-7
[23]
Colao, A., Vitale, G., Cappabianca, P., et al. (2004) Outcome of Cabergoline in Men with Prolactinoma: Effects of a 24-Mounth Treatment on Prolactin Levels, Tumor Mass, Recovery of Pituitary Function, and Semen Analysis. The Journal of Clinical Endocrinology & Metabolism, 89, 1704-1711. https://doi.org/10.1210/jc.2003-030979
[24]
Elfelehm E., Bchirm N., Rojbim I,m et al. (2016) Evolution of Macroprolactinomas under Medical Treatment. Annals of Endocrinology, 77, 329-371. (In French) https://doi.org/10.1016/j.ando.2016.07.270
[25]
Trévillot, V., Lassave, J., Cartier, C., et al. (2012) Endonasal Endoscopic Pituitary Surgery: About 121 Cases. French Annals of Otorhinolaryngology and Cervico-Facial Pathology, 129, 69-70. (In French) https://doi.org/10.1016/j.aforl.2012.07.184
[26]
Kassis, S., De Battista, J.C., Raverot, G., et al. (2009) [Endoscopy versus Microsurgery: Results in a Consecutive Series of Nonfunctioning Pituitary Adenomas]. Neurosurgery, 55, 607-615. (In French) https://doi.org/10.1016/j.neuchi.2009.05.003
[27]
Baldé, N.M., Ben Yaya, M., Poirier, J.Y., et al. (2005) Long-Term Prognosis of Non-Functional Pituitary Adenomas Operated on via the Transsphenoidal Approach. Annals of Endocrinology, 67, 416 p. (In French)
[28]
Sigounas, D.G., Sharpless, J.L., Cheng, D.M., Johnson, T.G., Senior, B.A. and Ewend, M.G. (2008) Predictors and Incidence of Central Diabetes Insipidus after Endoscopic Pituitary Surgery. Neurosurgery, 62, 71-79. https://doi.org/10.1227/01.NEU.0000311063.10745.D8
